Treatment with a CRH-1-receptor antagonist (R121919) does not affect weight or plasma leptin concentration in patients with major depression
- 31 March 2005
- journal article
- clinical trial
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 39 (2) , 173-177
- https://doi.org/10.1016/j.jpsychires.2004.06.006
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Central Nervous and Metabolic Effects of Intranasally Applied LeptinEndocrinology, 2004
- Human Urocortin II, a Selective Agonist for the Type 2 Corticotropin-Releasing Factor Receptor, Decreases Feeding and Drinking in the RatThe Journal of Pharmacology and Experimental Therapeutics, 2003
- The Corticotropin-Releasing Factor1 Receptor Antagonist R121919 Attenuates the Behavioral and Endocrine Responses to StressThe Journal of Pharmacology and Experimental Therapeutics, 2003
- The High-affinity Non-peptide CRH1Receptor Antagonist R121919 Attenuates Stress-induced Alterations in Plasma Oxytocin, Prolactin, and Testosterone Secretion in RatsPharmacopsychiatry, 2003
- Body Weight, the Tumor Necrosis Factor System, and Leptin Production during Treatment with Mirtazapine or VenlafaxinePharmacopsychiatry, 2002
- Low Leptin Levels but Norma Body Mass Indices in Patients with Depression or SchizophreniaNeuroendocrinology, 2001
- Effects of Neuropeptides and Leptin on Nutrient Partitioning: Dysregulations in ObesityAnnual Review of Medicine, 2001
- Neuropeptides and obesityNutrition, 2000
- Chronic Effects of a Nonpeptide Corticotropin-Releasing Hormone Type I Receptor Antagonist on Pituitary-Adrenal Function, Body Weight, and Metabolic RegulationEndocrinology, 1998
- Effects of Clozapine on Plasma Cytokine and Soluble Cytokine Receptor LevelsJournal of Clinical Psychopharmacology, 1996